drugset / Trial / NCT01331681

Intravitreal Aflibercept Injection in Vision Impairment Due to DME

NCT01331681

Phase 3 Completed 406 enrolled Bayer Regeneron Pharmaceuticals · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the efficacy of intravitreally (IVT) administered VEGF Trap-Eye on the best-corrected visual acuity (BCVA) assessed by the early treatment diabetic retinopathy study (ETDRS) chart in subjects with diabetic macular edema (DME) with central involvement

Timeline

Start
2011-05-09
Primary completion
2013-06-03
Completion
2015-03-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal